Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AV-COVID-19 Phase I Vaccine Trial
NCT04685603Phase 1Unknown
- Sponsor
- Ministry of Health of the Republic of Indonesia
- Start
- Dec 2020
- Primary completion
- Jan 2021
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of COVID-19 S-Vax loaded autologous dendritic cells in coronavirus disease 2019 (COVID-19) (9 arms), sponsored by Ministry of Health of the Republic of Indonesia. Primary endpoints: Frequency of solicited local and systemic reactogenicity adverse events at Day 7, Safety Laboratory Values (Serum Chemistry and Hematology) at Day 7 and 1 more. Status: unknown.
02
Drugs
COVID-19 S-Vax loaded autologous dendritic cells
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04685603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04685603.